Details of the Drug Combinations

General Information of This Drug (ID: DMQ4TJK)

Drug Name
Dutasteride   DMQ4TJK
Synonyms
Avodart; Avolve; Duagen; Dutasteride [USAN]; GG 745; GI 198745; Avidart (TN); Avodart (TN); Avodart, Dutasteride; Avolve (TN); Duagen (TN); Duprost (TN); Dutagen (TN); Dutas (TN); GG-745; GI-198745; GI-198745X; Dutasteride (JAN/USAN/INN); N-[2,5-bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide; Alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy-2',5'-xylidide; (1S,3aS,3bS,5aR,9aR,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (1S,3aS,3bS,5aR,9aR,9bS,11aS)-N-[2,5-bis(trifluoromethyl)phenyl]-9a,11a-dimethyl-7-oxo-1,2,3,3a,3b,4,5,5a,6,9b,10,11-dodecahydroindeno[5,4-f]quinoline-1-carboxamide; (5-alpha,17-beta)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide;dutasteride; (5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide
Indication
Disease Entry ICD 11 Status REF
Benign prostatic hyperplasia GA90 Approved [1]
Prostate adenocarcinoma N.A. Approved [2]
Prostate cancer 2C82.0 Phase 3 [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Dutasteride + Ruxolitinib DCVHHGC Ruxolitinib Hodgkin lymphoma (Cell Line: L-1236) [3]
------------------------------------------------------------------------------------
9 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Dutasteride + Finasteride DCRENW9 Finasteride Prostate Cancer [4]
Dutasteride + Bicalutamide DCN1TLS Bicalutamide Neoplasms, Prostate [5]
Tadalafil + Dutasteride DC7B0IQ Tadalafil Benign Prostate Hyperplasia [6]
Tamsulosin + Dutasteride DCA9CVA Tamsulosin Prostatic Hyperplasia [7]
Testosterone + Dutasteride DC5K27A Testosterone Aging [8]
Testosterone + Dutasteride DC1IGM6 Testosterone Contraception [9]
ABIRATERONE + Dutasteride DCECZF8 ABIRATERONE Prostate Cancer [10]
Goserelin + Dutasteride DC2MNA6 Goserelin Salivary Duct Carcinoma [11]
Nitazoxanide + Dutasteride DCXCQLL Nitazoxanide Covid19 [12]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7457).
2 Dutasteride FDA Label
3 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
4 ClinicalTrials.gov (NCT01342367) Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
5 ClinicalTrials.gov (NCT00470834) Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy
6 ClinicalTrials.gov (NCT01942551) Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride
7 ClinicalTrials.gov (NCT01657851) Bioequivalence - Duodart Against Avodart & Omnic
8 ClinicalTrials.gov (NCT00309855) Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men
9 ClinicalTrials.gov (NCT00399165) Oral Androgens in Man-4: (Short Title: Oral T-4)
10 ClinicalTrials.gov (NCT05705700) Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)
11 ClinicalTrials.gov (NCT05513365) Phase II Dutasteride in Combination With CAB vs CAB in SDC
12 ClinicalTrials.gov (NCT04729491) EAT-DUTA AndroCoV Trial